Incyte CORP Form 4 insider transactions

Sheila Denton, EVP & General Counsel of Incyte, reports the withholding of shares to cover tax obligations, resulting in an adjusted beneficial ownership of 30,343 shares.

Lee Heeson, EVP, Head of Incyte International, reports acquiring 26,447 shares of Incyte Corp common stock through restricted stock units.

Baker Bros. Advisors LP and related entities, including Julian and Felix Baker, reported changes in their beneficial ownership of Incyte Corp common stock due to the issuance of shares in lieu of director retainer fees.

Director Paul J. Clancy reports acquisition of Incyte shares via stock incentive plan and disposal of shares, according to a Form 4 filing.

Director Edmund Harrigan acquired 378 shares of Incyte Corp common stock at $66.10 per share on September 30, 2024, under the company's stock incentive plan.

Principal Accounting Officer Thomas Tray of Incyte Corp. reports selling shares of common stock on September 12th and 13th, 2024.

EVP Jonathan Dickinson reports the sale of Incyte Corp common stock in multiple transactions on September 12, 2024.

Steven H. Stein, Executive VP & Chief Medical Officer of Incyte Corp, reported the sale of 11,608 shares of common stock at a price of $60.63 on August 12, 2024.

Incyte Corp's EVP, Vijay K. Iyengar, disposed of 15,571 shares of common stock at $70 per share on July 25, 2024, according to a recent SEC filing.

EVP and Chief Medical Officer of Incyte, Steven H. Stein, reports acquisition of stock and option awards.

Principal Accounting Officer Tray Thomas reports acquisition of restricted stock units and stock options, along with disposition of shares to cover tax obligations.

Paula Swain, EVP of Human Resources at Incyte Corp, reports acquisition of stock and options, as well as disposition of shares to cover tax obligations.

Sheila A. Denton, EVP & General Counsel of Incyte Corp, reports the acquisition of restricted stock units and stock options.

EVP and GM of Dermatology US, Matteo Trotta, reports acquisition of restricted stock units and stock options in Incyte Corp.

Pablo J Cagnoni, President of R&D at Incyte Corp, reports acquisition of stock and options, as well as shares withheld for tax obligations.

Incyte Corp CEO Herve Hoppenot reports the acquisition of restricted stock units and stock options, along with the disposal of shares to cover tax obligations.

EVP, GMAPPS Vijay K. Iyengar reports acquisition of restricted stock units and stock options, along with disposition of shares to cover tax obligations.

Christiana Stamoulis, EVP & Chief Financial Officer of Incyte Corp, reports the acquisition of restricted stock units and stock options, as well as the disposition of shares to cover tax obligations.

Executive Vice President and General Manager of US at Incyte, Barry P. Flannelly, reports acquisition of restricted stock units, disposition of shares for tax obligations, sale of shares, and grant of employee stock options.

EVP & General Manager US of Incyte Corp, Barry P Flannelly, sold 8,148 shares of common stock at $60 per share on July 9, 2024.

Incyte Corp CEO Herve Hoppenot disposed of 41,723 shares of common stock to cover tax withholding obligations related to the settlement of RSUs and earned performance shares.

Barry P. Flannelly, EVP & General Manager US at Incyte Corp, disposed of 7,695 shares to cover tax obligations, leaving him with 58,682 shares.

Vijay K. Iyengar, EVP, GMAPPS of Incyte Corp, reports the disposal of 5,706 shares of common stock to cover tax obligations.

Christiana Stamoulis, EVP & Chief Financial Officer of Incyte Corp, reports the disposition of 6,870 shares of common stock to cover tax obligations.

Steven H. Stein, EVP & Chief Medical Officer of Incyte Corp, reports a transaction involving common stock due to tax withholding obligations.

Paula J Swain, EVP of Human Resources at Incyte Corp, reported disposing of 5,560 shares of common stock to cover tax withholding obligations.

Principal Accounting Officer Tray Thomas disposed of 844 shares of Incyte Corp stock to cover tax obligations arising from the settlement of restricted stock units.

Baker Bros. Advisors and related entities report changes in their beneficial ownership of Incyte Corp stock, including acquisitions of common stock in lieu of director fees.

Director Paul J. Clancy reports acquisition of 399 shares and disposition of shares of Incyte Corp common stock on June 28, 2024.

Director Edmund Harrigan acquired 409 shares of Incyte Corp common stock on June 28, 2024, in lieu of quarterly director retainer fees.